Lumiradx continues commercial expansion of its rapid microfluidic immunoassay hba1c test

Now available in europe, parts of the middle east, asia, latin america, and africa  early customers include gp offices and other community-based healthcare settings latest figures, released as part of world diabetes day, reveal that 1 in 10 adults are now living with diabetes and nearly half are undiagnosed1 the lumiradx hba1c test is designed to address the growing clinical need for accessible and reliable hba1c testing in community-based healthcare settings such as primary care, diabetes clinics, rural clinics, retail pharmacy & other decentralised healthcare settings the actively controlled microfluidic immunoassay is run on the highly portable lumiradx platform and designed for near-patient testing with connected results in under seven minutes the addition of hba1c to the rapidly growing lumiradx test menu, enables the consolidation of multiple instruments to a single, next-generation point of care platform; all with a common workflow london , nov. 14, 2022 /prnewswire/ -- lumiradx limited (nasdaq: lmdx), a next-generation point of care diagnostics company, today announced the continued commercial expansion of its hba1c test, for professional use across multiple care settings. used alongside the lumiradx platform, the test monitors known diabetic patients' hba1c levels and also serves as an aid in screening and identifying patients who may be at risk for developing diabetes.
LMDX Ratings Summary
LMDX Quant Ranking